Alzheimer's disease (AD) is the most prevalent neurodegenerative disease in ageing,
affecting around 46 million people worldwide but few treatments are currently available. The …

During aging, the cellular milieu of the brain exhibits tell-tale signs of compromised
bioenergetics, impaired adaptive neuroplasticity and resilience, aberrant neuronal network …

Importance Network hyperexcitability may contribute to cognitive dysfunction in patients with
Alzheimer disease (AD). Objective To determine the ability of the antiseizure drug …

Our incomplete understanding of the link between Alzheimer's Disease pathology and
symptomatology is a crucial obstacle for therapeutic success. Recently, translational studies …

Virtually all adults with Down syndrome (DS) show the neuropathological changes of
Alzheimer disease (AD) by the age of 40 years. This association is partially due to …

It is increasingly accepted that early cognitive impairment in Alzheimer's disease results in
considerable part from synaptic dysfunction caused by the accumulation of a range of …

Accumulation of misfolded and aggregated forms of tau protein in the brain is a
neuropathological hallmark of tauopathies, such as Alzheimer's disease and frontotemporal …

In an ever-increasing aged world, Alzheimer's disease (AD) represents the first cause of
dementia and one of the first chronic diseases in elderly people. With 55 million people …

2. King MA, Newton MR, Jackson GD, Fitt GJ, Mitchell LA, Silvapulle MJ, et al. Epileptology
of the first-seizure presentation: a clinical, electroencephalographic, and magnetic …

People with epilepsy—in particular, late-onset epilepsy of unknown aetiology—have an
elevated risk of dementia, and seizures have been detected in the early stages of Alzheimer …